Faculty

Grace M. Choong, M.D.

Clinical Studies

A Randomized Trial Of Neratinib, A Pan-ERBB Inhibitor, Alone Or In Combination With Palbociclib, A CDK4/6 Inhibitor, In Patients With HER2+ Gynecologic Cancers And Other Solid Tumors: A ComboMATCH Treatment Trial Rochester, MN This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.
A Single Arm Phase 1/2 Trial Of Abemaciclib + Avutometinib (VS-6766) + Fulvestrant In Metastatic HR+/HER2- Breast Cancer Rochester, MN
This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer.
The names of the study drugs involved in this study are:
- VS-6766
- Abemaciclib
- Fulvestrant

A Phase 1/2 Randomized Multi-Cohort Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Clinical Activity Of Mocertatug Rezetecan In Combination With Anti-Cancer Agents In Participants With Advanced Solid Tumors Rochester, MN Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable Mocertatug Rezetecan (Mo-Rez) is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.

A Randomized Trial Of Selumetinib And Olaparib Or Selumetinib Alone In Patients With Recurrent Or Persistent RAS Pathway Mutant Ovarian And Endometrial Cancers: A ComboMATCH Treatment Trial Jacksonville, FL Rochester, MN
The purpose of this phase II ComboMATCH treatment trial is to compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway.
Elacestrant Versus Standard Endocrine Therapy In Women And Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk Of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study Albert Lea, MN Scottsdale/Phoenix, AZ Eau Claire, WI Jacksonville, FL La Crosse, WI Mankato, MN Rochester, MN The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.